Literature DB >> 14657379

HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses.

Sayed F Abdelwahab1, Fiorenza Cocchi, Kenneth C Bagley, Roberta Kamin-Lewis, Robert C Gallo, Anthony DeVico, George K Lewis.   

Abstract

CD4+ T cells are required for immunity against many viral infections, including HIV-1 where a positive correlation has been observed between strong recall responses and low HIV-1 viral loads. Some HIV-1-specific CD4+ T cells are preferentially infected with HIV-1, whereas others escape infection by unknown mechanisms. One possibility is that some CD4+ T cells are protected from infection by the secretion of soluble HIV-suppressive factors, although it is not known whether these factors are produced during primary antigen-specific responses. Here, we show that soluble suppressive factors are produced against CXCR4 and CCR5 isolates of HIV-1 during the primary immune response of human CD4+ T cells. This activity requires antigenic stimulation of naïve CD4+ T cells. One anti-CXCR4 factor is macrophage-derived chemokine (chemokine ligand 22, CCL22), and anti-CCR5 factors include macrophage inflammatory protein-1 alpha (CCL3), macrophage inflammatory protein-1 beta (CCL4), and RANTES (regulated upon activation of normal T cells expressed and secreted) (CCL5). Intracellular staining confirms that CD3+CD4+ T cells are the source of the prototype HIV-1-inhibiting chemokines CCL22 and CCL4. These results show that CD4+ T cells secrete an evolving HIV-1-suppressive activity during the primary immune response and that this activity is comprised primarily of CC chemokines. The data also suggest that production of such factors should be considered in the design of vaccines against HIV-1 and as a mechanism whereby the host can control infections with this virus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14657379      PMCID: PMC299882          DOI: 10.1073/pnas.2035075100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Determination of lymphocyte division by flow cytometry.

Authors:  A B Lyons; C R Parish
Journal:  J Immunol Methods       Date:  1994-05-02       Impact factor: 2.303

2.  Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway.

Authors:  Kenneth C Bagley; Sayed F Abdelwahab; Robert G Tuskan; Timothy R Fouts; George K Lewis
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

3.  Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs).

Authors:  Lokesh Agrawal; Zainab Vanhorn-Ali; Ghalib Alkhatib
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

Review 4.  The staphylococcal enterotoxins and their relatives.

Authors:  P Marrack; J Kappler
Journal:  Science       Date:  1990-05-11       Impact factor: 47.728

5.  Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection.

Authors:  C E Mackewicz; L C Yang; J D Lifson; J A Levy
Journal:  Lancet       Date:  1994-12-17       Impact factor: 79.321

6.  Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor.

Authors:  Linqi Zhang; Wenjie Yu; Tian He; Jian Yu; Rebecca E Caffrey; Enrique A Dalmasso; Siyu Fu; Thang Pham; Jianfeng Mei; Jaclyn J Ho; Wenyong Zhang; Peter Lopez; David D Ho
Journal:  Science       Date:  2002-09-26       Impact factor: 47.728

7.  CD8 naive T cell counts decrease progressively in HIV-infected adults.

Authors:  M Roederer; J G Dubs; M T Anderson; P A Raju; L A Herzenberg; L A Herzenberg
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

8.  Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selectin on T cells during the virgin to memory cell transition.

Authors:  L J Picker; J R Treer; B Ferguson-Darnell; P A Collins; D Buck; L W Terstappen
Journal:  J Immunol       Date:  1993-02-01       Impact factor: 5.422

9.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

10.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  27 in total

1.  In vitro restoration of Th17 response during HIV infection with an antiretroviral drug and Th17 differentiation cytokines.

Authors:  Yelina Alvarez; Michael Tuen; Arthur Nàdas; Catarina E Hioe
Journal:  AIDS Res Hum Retroviruses       Date:  2011-12-01       Impact factor: 2.205

2.  Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforin.

Authors:  Sherri L Surman; Scott A Brown; Bart G Jones; David L Woodland; Julia L Hurwitz
Journal:  AIDS Res Hum Retroviruses       Date:  2010-07       Impact factor: 2.205

3.  Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus.

Authors:  D Noah Sather; Sara Carbonetti; Jenny Kehayia; Zane Kraft; Iliyana Mikell; Johannes F Scheid; Florian Klein; Leonidas Stamatatos
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

4.  Primary HIV-1 Infection: Diagnosis, Pathogenesis, and Treatment.

Authors:  Malini Soogoor; Eric S Daar
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

5.  Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases.

Authors:  Fiorenza Cocchi; Anthony L DeVico; Wuyuan Lu; Mikulas Popovic; Olga Latinovic; Mohammad M Sajadi; Robert R Redfield; Mark K Lafferty; Massimo Galli; Alfredo Garzino-Demo; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

6.  Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production.

Authors:  Anthony R Geonnotti; Miroslawa Bilska; Xing Yuan; Christina Ochsenbauer; Tara G Edmonds; John C Kappes; Hua-Xin Liao; Barton F Haynes; David C Montefiori
Journal:  AIDS Res Hum Retroviruses       Date:  2010-03       Impact factor: 2.205

Review 7.  Primary human immunodeficiency virus type 1 infection.

Authors:  Malini Soogoor; Eric S Daar
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

8.  Single-cell transcriptional landscapes reveal HIV-1-driven aberrant host gene transcription as a potential therapeutic target.

Authors:  Runxia Liu; Yang-Hui Jimmy Yeh; Ales Varabyou; Jack A Collora; Scott Sherrill-Mix; C Conover Talbot; Sameet Mehta; Kristen Albrecht; Haiping Hao; Hao Zhang; Ross A Pollack; Subul A Beg; Rachela M Calvi; Jianfei Hu; Christine M Durand; Richard F Ambinder; Rebecca Hoh; Steven G Deeks; Jennifer Chiarella; Serena Spudich; Daniel C Douek; Frederic D Bushman; Mihaela Pertea; Ya-Chi Ho
Journal:  Sci Transl Med       Date:  2020-05-13       Impact factor: 17.956

9.  Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection.

Authors:  Gurvinder Kaur; Michael Tuen; Diana Virland; Sandra Cohen; Narinder K Mehra; Christian Münz; Sayed Abdelwahab; Alfredo Garzino-Demo; Catarina E Hioe
Journal:  Virology       Date:  2007-09-04       Impact factor: 3.616

10.  Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users.

Authors:  Kristi Huik; Radko Avi; Merit Pauskar; Eveli Kallas; Ene-Ly Jõgeda; Tõnis Karki; Kristina Marsh; Don Des Jarlais; Anneli Uusküla; Irja Lutsar
Journal:  Infect Genet Evol       Date:  2013-08-17       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.